Cargando…
SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption. https://bit.ly/3hCw5dq
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411273/ https://www.ncbi.nlm.nih.gov/pubmed/32764115 http://dx.doi.org/10.1183/13993003.02114-2020 |